Stefano P.
- Country
- Italy
- Department
- Medical oncology
Research Overview
- Evaluation of MCLA-129, a Bispecific Antibody Targeting EGFR and c-MET, Alone and in Combination with Chemotherapy and Osimertinib in Advanced Solid Tumors
- Phase III Trial Comparing FOLFIRI Plus Cetuximab Versus Bevacizumab in First-Line Treatment of mCRC with RAS/BRAF Wild-Type Tissue and Mutated Liquid Biopsy
Data & Insights
Has run more than one trial at 4 of 110 partner sites.
Specializations
Oncology Focus
This investigator specializes in treating advanced solid tumors, with particular emphasis on non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
- Solid Tumor Management
- Advanced NSCLC Treatment
- Metastatic Colorectal Cancer Care
The investigator's work encompasses evaluation of novel therapeutic approaches for these conditions.
Therapeutic Innovation
Areas of therapeutic interest include targeted antibody treatments and combination therapy approaches in oncology.
- Novel Antibody Therapeutics
- Combination Treatment Strategies
- Personalized Medicine Applications
The focus extends to investigating response rates and survival outcomes in cancer treatment.
Precision Medicine
Expertise in molecular profiling and biomarker-driven treatment selection, particularly in relation to RAS/BRAF mutations.
- Liquid Biopsy Applications
- Mutation Analysis
- Treatment Response Assessment
The investigator evaluates treatment efficacy through progression-free survival and response duration metrics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.